Myriad's BRACAnalysis CDx Proves Mettle In Patient Selection For AstraZeneca's Olaparib Therapy
Executive Summary
Patients with HER2- metastatic breast cancer and who were tested positive for BRCA1/2 mutations with Myriad's BRACAnalysis CDx companion diagnostic showed they benefitted more from AstraZeneca's Lynparza (olaparib) than standard chemotherapy, according to results from a Phase III trial.